X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The acquisition supplements BioVaxys' existing cancer vaccine portfolio with the addition of DPX-Survivac (maveropepimut-S), a DPX™-formulated cancer vaccine that delivers antigenic peptides from survivin, a cancer antigen commonly overexpressed in advanced cancers.
Lead Product(s): Maveropepimut-S,Pembrolizumab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: DPX-Survivac
Highest Development Status: Phase IIProduct Type: Vaccine
Recipient: Immunovaccine Technologies
Deal Size: $25.7 million Upfront Cash: $25.7 million
Deal Type: Acquisition February 12, 2024
Details:
Papilocare (hyaluronic acid) vaginal gel is the first treatment that has been scientifically proven to have a very high success rate in eliminating not only the human papiloma virus (HPV), but also precancerous lesions of the cervix.
Lead Product(s): Hyaluronic Acid,Coriolus Versicolor
Therapeutic Area: Infections and Infectious Diseases Product Name: Papilocare
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: ProCare Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 19, 2022
Details:
BVX-1021 is hapten-modified recombinant S1 subunit of the spike protein from the SARS1 virus, whereas BVX-0320, is a hapten-modified recombinant S1 subunit of the spike protein from SARS-CoV-2 ("SARS2"), the virus which causes Covid-19.
Lead Product(s): BVX-1021,BVX-0320
Therapeutic Area: Infections and Infectious Diseases Product Name: BVX-1021
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: The Ohio State University
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2022
Details:
BVX-1021 using a new batch of recombinant SARS-1 protein from the supplier that screened out the extraneous protein aggregate, has been synthesized using the purified SARS1 protein, OSU is now able to complete the neutralizing antibody studies.
Lead Product(s): BVX-1021,BVX-0320
Therapeutic Area: Infections and Infectious Diseases Product Name: BVX-1021
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Merck Millipore
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
BVX-0918A, BioVaxys’s cancer vaccines are created by extracting a patient’s own cancer cells, chemically treating them with a hapten, and re-injecting them into the patient to induce an immune response to proteins which are otherwise not immunogenic.
Lead Product(s): BVX-0918
Therapeutic Area: Oncology Product Name: BVX-0918
Highest Development Status: IND EnablingProduct Type: Vaccine
Recipient: Bio Elpida
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Details:
BioVaxys expects to be able to prepare its regulatory submission for a EU Phase I study of BVX-0918 in Stage III/Stage IV ovarian cancer near the end of this year, with vaccine supply for the planned clinical study available early May 2022.
Lead Product(s): BVX-0918
Therapeutic Area: Oncology Product Name: BVX-0918
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Hospices Civils de Lyon
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 18, 2022
Details:
BioVaxys’s cancer vaccine BVX-0918C, created by extracting a patient’s own cancer cells, chemically treating them with a hapten, and re-injecting them into patient to induce an immune response to proteins which are otherwise not immunogenic.
Lead Product(s): BVX-0918C
Therapeutic Area: Oncology Product Name: BVX-0918C
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Procare Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
Access to ovarian cancer tumor cells is a critical step enabling BioVaxys to validate the manufacturing process for BVX-0918, the Company's autologous haptenized tumor cell vaccine for late-stage ovarian cancer.
Lead Product(s): BVX-0918
Therapeutic Area: Oncology Product Name: BVX-0918
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Deaconess Research Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 25, 2022
Details:
BVX-1021 is the subject of an ongoing research collaboration between The Ohio State University and BioVaxys, announced in December 2021, that is evaluating the Company's novel approach for a "universal vaccine" that can treat a broad range of sarbecoviruses.
Lead Product(s): BVX-1021,BVX-0320
Therapeutic Area: Infections and Infectious Diseases Product Name: BVX-1021
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: The Ohio State University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 17, 2022
Details:
Biovaxys intends to leverage its haptenized viral protein vaccine platform to induce immunity against all or most sarbecoviruses by immunizing people, with a novel vaccine composed of the dinitrophenyl (“DNP”)-modified S-spike protein of SARS-CoV-1.
Lead Product(s): Dinitrophenyl Modified S-spike Protein of SARS-CoV-1
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
